| Study |
N |
Follow up |
Biochemical Changes |
BMD |
| |
|
|
PTH |
ALP |
Vit D |
Ca |
Femoral neck |
Lumbar Spine |
Total Hip |
Vilrassa
2011 |
59 (F) |
36m |
Inc |
-- |
Dec |
No sig diff |
-12.9% |
-6.9% |
-- |
Valderas
2009 |
26 (F)
post-menopausal |
3.5±1.1y |
Inc |
No sig diff |
No sig diff |
No sig diff |
No sig diff |
No sig diff |
-- |
D de Campos
2008 |
30 (F) |
8.5±0.7y |
Inc |
Inc |
Dec |
No sig diff |
Osteoporosis in 13%
Osteopenia in 40% |
Osteopenia in 67% |
-- |
| Fleischer 2008 |
23 |
12m |
Inc* |
-- |
No sig diff** |
No sig diff** |
-9.2% |
No sig diff |
-8.0% |
| Mahdy 2008 |
70 (M+F) |
1y |
Inc |
No sig diff |
No sig diff** |
No sig diff** |
BMD by DEXA decreased by 3.198% and bone mineral content by 9.02% |
diGiorgi
2007 |
403 (M+F)
Gastric Bypass |
2y |
Inc |
Inc |
Inc** |
No sig diff ** |
BMD not assessed, however the article suggests that with adequate supplementation the risk of bone loss can be attenuated. |
131 (M+F)
LAGB |
2y |
Inc*** |
Inc*** |
No sig diff ** |
No sig diff ** |
| Coates 2004 |
25 (M+F) |
11±3m |
|
No sig diff |
Inc** |
No sig diff** |
Urinary NTx (marker of bone resorption) increased by 288% and osetocalcin (marker of bone formation) by 53% |
Parfitt
1999 |
21 (F) |
3-14yr |
Inc |
Inc |
|
Dec |
Trabecular bone volume significantly reduced |